FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets, developed by AbbVie, as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease. This approval offers a new approach to controlling motor symptoms, with JUVMO™ being taken once daily with or without levodopa therapy. The approval is supported by the Phase 3 TEMPO program, which demonstrated significant improvements in daily functioning and increased 'on' time without troublesome dyskinesia, alongside a favorable safety profile.